Intratumor CD8+ TRMs are a subpopulation with identified antitumor functions, in which CD103 is predominantly expressed on the surface, and intra-tumor CD103+ TILs might serve as a prognostic marker for patients with urothelial cell carcinoma of the bladder (48). The gene discussed is CD8A; the disease is neoplasm.